Prudential Financial
LOGC

Prudential Financial’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Prudential Financial’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-98,600
Closed -$27K – 2748
2022
Q3 		$27K Buy
98,600
+34,600
+54% +$13.7K ﹤0.01% 2616
2022
Q2 		$23K Buy
+64,000
New +$32.4K ﹤0.01% 2642

Prudential Financial's LOGC Position: Q4 2022 in Review

Prudential Financial sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 98,600 shares — an estimated $27K sold.

Prudential Financial first reported a position in LOGC in Q2 2022 and held it in 2 quarters. The position peaked at $27K in Q3 2022. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

  • Prudential Financial reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Prudential Financial sold 98,600 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $27K.
  • Prudential Financial first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Prudential Financial's LogicBio Therapeutics, Inc. Common Stock position peaked at $27K in Q3 2022.
  • 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Prudential Financial's 13F filing for Q4 2022, filed 14 Feb 2023.